stars 1 stars 2 stars 3

LexaGene Life Sciences is an early-stage company developing a novel automated PCR-based bioburden testing system. The technology will be a significant improvement in the key needs of speed, ease-of-use, and sensitivity for >95% of microbial contaminants. Our initial target market is the biopharmaceutical manufacturing industry.

LexaGene Questions

The LexaGene annual revenue was $4 million in 2026.

Steve Armstrong is the COO of LexaGene.

1 people are employed at LexaGene.

LexaGene is based in Beverly, Massachusetts.

The NAICS codes for LexaGene are [541, 54171, 541714, 54, 5417, 541715].

The SIC codes for LexaGene are [87, 873].

Top LexaGene Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users